Publications by authors named "C Ohata"
Cadmium is a contributing factor to cardiovascular diseases and highly toxic to vascular endothelial cells. It has a distinct mode of injury, causing the de-endothelialization of regions in the monolayer structure of endothelial cells in a concentration-dependent manner. However, the specific molecules involved in the cadmium toxicity of endothelial cells remain unclear.
View Article and Find Full Text PDFArticle Synopsis
- Clinical trials often leave out elderly patients, leading to limited safety and efficacy data for biologics in this demographic.
- A study comparing elderly (≥65 years) and younger (<65 years) patients using data from the West Japan Psoriasis Registry found that treatment-ending adverse events were more common in the elderly, and malignant neoplasms occurred at higher rates.
- Despite some safety concerns, biologics were effective for both age groups, with no significant differences in treatment outcomes or quality of life indicators between the elderly and younger patients.
Article Synopsis
- The study explored sex differences in how home blood pressure (HBP) measurements predict cardiovascular events in men and women with hypertension, analyzing data from the HOMED-BP study.
- Results showed that increases in systolic HBP significantly raised cardiovascular risk in women at both baseline and during treatment, while it did not predict events in men at baseline.
- Although on-treatment HBP was linked to cardiovascular risk for both sexes, the risk increase was notably higher for women, highlighting the need for better HBP management in women.
Introduction: Evidence on treatment effectiveness in patients with psoriasis having anxiety or depressive symptoms helps shared decision-making. This single-arm, open-label, prospective study-ProLOGUE-was conducted to assess the effectiveness of brodalumab on self-assessed anxiety and depressive symptoms in Japanese patients with psoriasis.
Methods: Patients aged ≥ 18 years with plaque psoriasis without peripheral arthritis symptoms who had responded inadequately to current therapies were enrolled at 15 Japanese facilities and received brodalumab 210 mg subcutaneously.